What we do Ambalal Sarabhai Enterprises Ltd is an Indian multinational company engaged in pharmaceuticals, molecular diagnostics, APIs, effervescent formulations, and scientific instruments manufacturing and marketing. |
Founded in 1,977 |
Market share A seasoned player in Indian pharma and healthcare with growing international presence in molecular diagnostics and niche APIs. |
Problem solved Offers essential medicines, novel drug delivery systems, diagnostic kits, and scientific instruments to improve healthcare accessibility and treatment. |
Top clients or who we serve Serves pharmaceutical markets globally including domestic hospitals, overseas distributors, diagnostics companies, and research labs (B2B and B2C). |
Key management Kartikeya V. Sarabhai (Executive Chairman), Mohal K. Sarabhai (Managing Director), Chaula M. Shastri (Whole-time Director) |
Our journey and innovations Started in 1977; technical collaborations for insulin; formed joint ventures for anti-cancer drugs; expanded into diagnostics and novel effervescent drugs; upgraded manufacturing with USFDA and European approvals. |
Where we operate Primarily India, USA, Europe, and other international markets through subsidiaries and joint ventures. |
Top products or what we offer Pharmaceutical formulations, Active Pharmaceutical Ingredients, molecular diagnostics kits, effervescent drugs, and scientific instruments under various subsidiaries. |
Top brands Asence Pharma (oncology and APIs), Sarabhai Chemicals (oncology), Suvik Hitek (generics and veterinary), Synbiotics (fermentation-based antifungals), Systronics (analytical instruments), Vovantis Laboratories (effervescent products) |
Raw materials needed Active pharmaceutical ingredients, fermentation substrates, electronic components, chemical precursors for drug synthesis. |
Raw materials supplier Multiple domestic and international suppliers aligned with regulatory standards. |
Recurring vs cyclical contribution Revenue is a mix of recurring sales from pharmaceuticals and diagnostics with some cyclical investment in R&D and expansions. |
Our industry position Established domestic leader in select specialty pharma and niche diagnostics; growing export footprint. |
Financial highlights FY2024-25 revenue Rs. 196.19 Cr; net profit Rs. 4.93 Cr; steady growth in turnover and profitability over previous year. |
Geographical revenue split Domestic revenue Rs. 126.65 Cr; export revenue Rs. 69.53 Cr. |
Order book - |
Whats driving growth Focus on oncology APIs, molecular diagnostics expansion, novel formulations, and regulatory approvals in US and Europe markets. |
Our future plans Expansion of oncology and synthetic API plant; new product launches; regulatory accreditations to boost exports. |
Our green promise - |
Our people and values Governed by robust corporate governance practices with a committed board, promoting ethical standards and employee welfare. |
Key challenges ahead Navigating stringent regulatory environments, competition in pharma generics and diagnostics, and sustaining innovation pipeline. |
Interesting facts Among India’s oldest pharma health care companies with diversified portfolio spanning pharma, diagnostics, and electronics sectors. |
Risks and strategy Mitigates risks via regulatory compliance, diversified portfolios, technology collaborations, and robust internal controls. |
